US equities
|
MU
$913.78
▲+4.13%
TSLA
$394.33
▲+5.94%
NVDA
$216.38
▲+2.57%
SPCX
$148.65
▲+0.79%
META
$634.91
▼-1.20%
AAPL
$343.46
▼-1.23%
SNDK
$1,273.41
▲+2.86%
INTC
$91.84
▲+5.62%
MU
$913.78
▲+4.13%
TSLA
$394.33
▲+5.94%
NVDA
$216.38
▲+2.57%
SPCX
$148.65
▲+0.79%
META
$634.91
▼-1.20%
AAPL
$343.46
▼-1.23%
SNDK
$1,273.41
▲+2.86%
INTC
$91.84
▲+5.62%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
ABVC BioPharma, Inc. - Common Stock
(NQ:
ABVC
)
1.050
+0.010 (+0.96%)
Delayed Quote
Updated: 1:30 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about ABVC BioPharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders
June 23, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Artificial Intelligence
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders
June 23, 2026
SILICON VALLEY, CA - June 23, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) (“ABVC” or the “Company”), a clinical-stage biopharmaceutical company focused on botanical-derived therapeutics...
Via
TheNewswire.com
Topics
Artificial Intelligence
ABVC BioPharma Reports 2025 Form 10-K
March 03, 2026
Total Assets Increase 179% to $21.06 Million as Company Strengthens Asset-Backed Licensing Model
Via
TheNewswire.com
ABVC BioPharma Reports 2025 Form 10-K
March 03, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ABVC BioPharma Provides Corporate and Structural Update
February 24, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
ABVC BioPharma Provides Corporate and Structural Update
February 24, 2026
SILICON VALLEY, CA - February 24, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) (“ABVC” or the “Company”), a clinical-stage biopharmaceutical company focused on botanical-derived...
Via
TheNewswire.com
Topics
Intellectual Property
ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States
December 02, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States
December 02, 2025
Via
TheNewswire.com
ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030
November 26, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030
November 26, 2025
Via
TheNewswire.com
ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received
November 21, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received
November 21, 2025
Via
TheNewswire.com
ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million
November 18, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Artificial Intelligence
ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million
November 18, 2025
Via
TheNewswire.com
Topics
Artificial Intelligence
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025
November 03, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025
November 03, 2025
Via
TheNewswire.com
ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950
October 31, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950
October 31, 2025
Via
TheNewswire.com
ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology
October 17, 2025
Via
TheNewswire.com
ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology
October 17, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production
October 08, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production
October 08, 2025
Via
TheNewswire.com
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model
September 19, 2025
Via
TheNewswire.com
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model
September 19, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025
August 29, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025
August 29, 2025
Via
TheNewswire.com
BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration
August 27, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration
August 27, 2025
Via
TheNewswire.com
ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing Deal
August 22, 2025
Via
TheNewswire.com
ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing Deal
August 22, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
< Previous
1
2
3
4
5
6
7
Next >
